|
 |
| |
| Anhui Biochem United Pharmaceutical Co., Ltd is one of the leading pharmaceutical |
| manufacturing enterprises in
China specializing in the development of high quality |
| Anti-HIV/AIDS intermediates, active pharmaceutical ingredients (APIs) and finished |
| pharmaceutical products (FPPs). The company has rapidly integrated scientific |
| research, development and production specializing in the field of synthetic |
| technology of chiral compounds. The mission of the company is to develop high-quality |
| products with updated science and technology innovation to help save lives. |
|
| |
| Company highlights include: |
| · |
Approval by Health Canada for lamivudine API. |
| · |
Active partnerships with multinational pharmaceutical companies. |
| · |
China SFDA grants GMP approval for Lafutidine API with GMP certificate |
| |
(No.: 皖J0253). |
| · |
China SFDA grants GMP approval for Lamivudine API with GMP certificate |
| |
(No.: 皖K0276). |
| · |
China SFDA grants GMP approval for Anhui Biochem (Bio-Pharma) Co., Ltd. |
| · |
USD 10 million capital investment from UK investment fund. |
| · |
Selegiline Hydrochloride Capsule which approved by China SFDA with GMP certificate |
| |
has come onto the market. Now we are registering it and looking for business partners |
| |
around the world. |
|
| |
| Investments & Acquisitions: |
| · |
In June 2007, the company received a USD 10 million investment by QVT Fund LP (UK). |
| · |
In September 2007, the company invested RMB 160 million (USD 23 million) to expand |
| |
its API manufacturing base. |
| · |
In April 2008, the company invested RMB 130.7million (USD 19 million) to acquire a |
| |
bio-pharmaceutical company located at Hi-Tech Development Zone in Hefei, to set up |
| |
a subsidiary – Anhui Biochem (Bio-Pharma) Co., Ltd – for
R&D and manufacture of
|
| |
the finished pharmaceutical products (FPPs) for hepatitis B and HIV/AIDS. |
| · |
In December 2008, Anhui Biochem United Pharmaceutical Co., Ltd was permitted to
|
| |
prepare for establishing a subsidiary: Anhui Biochem Medical Sales Co., Ltd. |
| |
In March 2009, Anhui Biochem Medical Sales Co., Ltd was inspected and approved |
| |
by Anhui Food & Drug Administration. |
| · |
The total registered capital of the company is RMB 510 million (USD 75 million). |
|
| |
| The total site area of the company is 205,128m2(308 acres), including the API |
| manufacturing site of 110,556 m2 (166 acres), the FPPs manufacturing site of |
| 77,256 m2(116 acres) and the R&D base of 17,316 m2 (26 acres). |
|
| |
| The company has established a well-equipped R&D team with 5 Doctors and 12 Masters, |
| they are working under the
direction of the senior engineers who are honored by the |
| State Council subsidy. The company is controlled by the total quality management |
| system, and also persists in the idea of green environment protection through use of |
| modern facilities and utilities for treatment of the waste liquid and gas.
|
| |
|
|
|
|
|
